Opportunity overview
The All Wales Medical Genomics Service (AWMGS) has routinely utilised Multiplex Ligation-Dependent Probe Amplification (MLPA) as a diagnostic tool for identifying Copy Number Variations (CNVs)—including deletions and duplications—across a range of genetic disorders. This testing supports clinical decision-making and patient treatment strategies.MLPA technology involves the use of oligonucleotide probe pairs that hybridise to specific DNA sequences within target genes. When both probes bind adjacently at a site of interest, they are ligated and subsequently amplified via Polymerase Chain Reaction (PCR). The amplified DNA fragments are then separated by capillary electrophoresis and analysed to detect CNVs.Since its inception, AWMGS has exclusively sourced MLPA probes and reagents from MRC Holland, a Netherlands-based supplier recognised for its specialised products in molecular diagnostics.
Awarded to
Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.
MRC Holland
- Contract value
- £96k
- Awarded
- Not supplied
- Contract signed
- 2 Jan 2026
- Including VAT
- £115.2k
- Award ID
- 1
- Status
- active
- Identifier
- GB-PPON PRWG-4369-GJNP
- Location
- Amsterdam, NL, 1057 DI, Netherlands
Classification
No classification was supplied.
Lots
- Lot 1Value not stated
Documents and notices
- Contract details notice on Find a TenderOpen source ↗